---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-132132"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2024-12-27T23:59:59+00:00"
generated_at: "2026-05-28T23:01:00.670460+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences enters up to $5M equity purchase agreement with investor

## Summary
- Equity purchase agreement for up to $5M over 36 months; pricing at 93% of prior-day VWAP with a true-up mechanism.
- Investor receives 17,300 shares and pre-funded warrant for 21,015 shares as commitment fee; short selling prohibited.
- Issuance capped at 19.9% of outstanding shares unless stockholder approval or price exceeds Nasdaq Official Closing Price thresholds.
- Proceeds expected for working capital and merger with Vyome Therapeutics; 66% of net proceeds must prepay existing convertible note.
- Company filed S-1 to register resale of shares; agreement may be terminated by Company on 5 days' notice.

## SEC filing metadata
- accession: 0001104659-24-132132
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2024-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000110465924132132/0001104659-24-132132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000110465924132132/tm2431533d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-132132
- JSON: https://secwatch.observer/filing/0001104659-24-132132.json
- Plain text: https://secwatch.observer/filing/0001104659-24-132132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.